"The field of fluorescence in vivo imaging is already beginning to have a profound impact on the life-science and healthcare space," said Kirtland Poss, President and CEO of VisEn. "Since VisEn's founding, it has been our mission to work with leaders in the field to enable and support continued innovation, application, and expansion of the very best in fluorescence in vivo imaging technology. While we generally respect the contributions of Caliper/Xenogen to the field of bioluminescence imaging, we believe it is clear, and also fundamentally understood in the industry, that that the basic methods of fluorescence in vivo imaging were well known and in use before the priority date of the '851 patent, and therefore that the claims therein are clearly invalid. With this action today, our continued aim is to enable customers and partners in the space to innovate, apply and expand the power of fluorescence in vivo imaging broadly in their programs worldwide. We are confident that the rich history of optical in vivo imaging and the clear sequence of prior art references speak for themselves, and we look forward to continuing the development of all aspects of molecular imaging along with the leadership in the field."
The inter partes re-examination action filed with the USPTO is a matter of public record, and is posted at http://www.visenmedical.com .
About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence in vivo
imaging technologies initially developed by industry-leading researchers
and clinicians at the Massachusetts General Hospital and Harvard Medical
School. VisEn develops and commercializes the industry's highest performing
fluorescence in vivo imaging technology platforms, from research through
medicine. The Company also works directly with large pharmace
|SOURCE VisEn Medical, Inc.|
Copyright©2007 PR Newswire.